Healthcare professionals are inundated by product-related promotional content from pharma firms and want less of that but more on areas such as safety, efficacy and real-world evidence, a new survey on engaging digitally-savvy physicians indicates. Spain emerges as a stand-out market where pharma appears to have fared relatively well in mapping physician preferences to their marketing activities.
Healthcare Professionals (HCP)s may have turned more digitally savvy than ever amid the pandemic but pharma hasn’t quite delivered the goods so far in terms of effective or customer-centric engagement with physicians, a new global survey by Indegene, a global provider of healthcare solutions to the industry, indicates.
The study, which covered 984 physicians across the US, Europe, India and China, revealed that 70% of HCPs felt that...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
